↑Reichl S, Müller-Goymann CC (January 2003). "The use of a porcine organotypic cornea construct for permeation studies from formulations containing befunolol hydrochloride". International Journal of Pharmaceutics. 250 (1): 191–201. doi:10.1016/S0378-5173(02)00541-0. PMID12480285.
↑Takayanagi I, Koike K (January 1985). "A beta-adrenoceptor blocking agent, befunolol as a partial agonist in isolated organs". General Pharmacology. 16 (3): 265–267. doi:10.1016/0306-3623(85)90080-1. PMID2862092.
↑Pharmaceutical Manufacturing Encyclopedia (3rd reviseded.). Norwich, N.Y.: William Andrew Publishing. January 14, 2008. p.542. ISBN978-0815515265.
↑Lednicer D (1998). Strategies for Organic Drug Synthesis and Design. Canada: John Wiley & Sons. pp.37–41. ISBN0-471-19657-6.
↑US 3853923,Ito K, Ikemoto M, Kimura K, Nakanishi T,"2-Substituted-(2-hydroxy-3-lower alkaminopropoxy)-benzofurans",issued 1974, assigned to Kakenyaku Kako KK